Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
By J. Llovet, Jordi Bruix1 , 2. Hepatology, 2003
3,017 citations recorded by the source corpus.
Subfields: Hepatology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/47f775e5ea4acf2c2b43ff52de9d070844186c6a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Amit G. Singal
- Alejandro Forner1 , 2
- L. Kulik
- Andrew X. Zhu
In Pathology and Forensic Medicine
- Riccardo Lencioni
- J. Llovet
- Jordi Bruix1 , 2
- T. de Baère
- Andrew X. Zhu
- V. Mazzaferro
- Alejandro Forner1 , 2
- María E. Reig1 , 2
Citations in the corpus
- Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma (2016, background): “Chemoembolization is considered the standard of care for BCLC B patients based on improved survival compared to best supportive care.(5-7) Also, the applicability of cTACE is acknowledged for BCLC A patients ineligible for recommended treatments (stage migration).”
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (2007, background): “TACE is an effective option for patients with intermediate HCC [8,15].”
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “, World Health Organization (WHO) criteria [536], the reported rate of objective response ranges between 16 and 60% [513, 517].”
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016, background): “These patients are defined as being asymptomatic, with non-invasive, multinodular, unresectable tumors and adequate preservation of liver function [3–7].”
- Sorafenib in advanced hepatocellular carcinoma. (2008, neutral): “Radiofrequency ablation 17 (6) 12 (4) Radiotherapy** 13 (4) 15 ( 5 )”
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (2016, methodology): “4 months—is consistent with the data reported in the previous metaanalyses.((14,15)) Analysis of overall survival by year of publication showed that clinical studies published after 2002 reported longer median survival and higher 3-year survival rate than those published until 2002.”
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, background): “Less than 2% of treated patients achieve a complete response [333].”
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, background): “In intermediate-stage HCC (BCLC B), locoregional therapies such as transarterial chemoembolization (TACE) 173 and TARE 91,174 provide a median OS of 26–30 months, with a meta-analysis finding no significant difference in OS between the two modalities (0.55 months, 95% CI −1.95 to 3.05 months) 175 .”
- Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010, background): “It is important to note that arterial embolization without associated chemotherapy can induce a relevant rate of objective tumor response.(80) However, there is no proof of a positive impact in survival as proven for chemoembolization.”
- Management of hepatocellular carcinoma (2005, neutral): “In contrast, no improvement in survival was found for tamoxifen [18].”